Mohamed A, et al. - From 1970 to 2015, researchers assessed the data from 1500 prospective studies to elaborate the effectiveness and tolerability of cisplatin, weekly vs triweekly in locally advanced squamous cell carcinoma of the head and neck. They observed locoregional control, 58% vs 61%; 2-year overall survival (OS), 74% vs 67%; 2-year progression-free survival (PFS), 69% vs 62%; and grade 3 to 5 toxicities, 36% vs 40% for weekly vs triweekly groups. Overall, they preferred weekly or triweekly cisplatin utilization in locally advanced squamous cell carcinoma of the head and neck with comparable tolerability.